<DOC>
	<DOCNO>NCT02858570</DOCNO>
	<brief_summary>TYPE / DESIGN STUDY : Clinical trial phase II / III , randomize , double-blind , national multi-center , total 1,644 research participant stratify 3 group accord age start primary vaccination schedule ( Stratum I - 11 19 year , Stratum II - 1 10 year ; Stratum III - less 1 year old ) . BACKGROUND / STUDY CASE : Clinical trial phase II / III , purpose evaluate immunogenicity , safety reactogenicity vaccine meningococcus C , conjugate tetanus toxoid , develop Bio-Manguinhos / FIOCRUZ ( MenCC-Bio ) . The hypothesis study MenCC-BIO vaccine safe inferior term immunogenicity comparator vaccine currently available National Immunization Program child 's immunization schedule . Thus , MenCC-Bio vaccine may meet need expansion target age group vaccination routine public health service available National Immunization Program strategy ensure sustainability self-sufficiency vaccination policy . OBJECTIVES PRIMARY : To assess immunogenicity MenCC Bio-vaccine patient 3 month 19 year age , relation vaccine meningococcus C currently provide National Immunization Program . To evaluate safety reactogenicity MenCC Bio-vaccine patient 3 month 19 year old . SECONDARY OBJECTIVES : Evaluate cellular immune component meningococcal C conjugate vaccine subset survey participant , age 11 19 year . STUDY POPULATION : Individuals sex , healthy , age 3 month 19 year , attend campus Fiocruz / Rio de Janeiro , municipal health unit Rio de Janeiro ( live area cover municipal unit health participant ) fit study eligibility criterion . NUMBER OF CENTRES : Two Clinical site . STUDY DURATION : Estimate 19 month . INTERVENTION / TREATMENT : Two intervention group ( MenCC-BIO Vaccine Comparator ) three age group , specific vaccination schedule . For age group I II apply 2 dos ideal interval 6 month . In stratum III , recommend 3 dos vaccine , age 3 , 5 12 month age , accord calendar National Immunization Program . OUTCOMES PRIMARY : Immunogenicity : Proportion seroconversion define seronegative status change ( title bactericidal antibody child rabbit complement 1 : 8 ) seropositive ( titer bactericidal antibody large rabbit complement equal 1 : 8 ) increase 4 time post vaccinal compare pre-vacianais full vaccination schedule age stratum . Geometric mean antibody titer ( TGM ) pre- post-vaccination , vaccine group , ratio security full vaccination schedule age stratum . Safety reactogenicity : Frequency intensity adverse event solicit unsolicited , occur 30 day vaccination . SECONDARY OUTCOME : cell detection B ( CD19 + ) memory phenotype ( CD27 + IgD + , CD27 + IgD ) subgroup patient age stratum I ( 11-19 year old ) . ADDITIONAL INFORMATION age escalation , interim analysis inter-layer security approval Security Independent Monitoring Committee progression next low age stratum .</brief_summary>
	<brief_title>Conjugate Vaccine Against Meningococcus C Brazilian Project</brief_title>
	<detailed_description>Status : Not yet recruit : participant yet recruit .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Be current national calendar vaccination age group ( except meningitis C vaccine see exclusion criterion ) . Available monitoring throughout study period . Willing provide name , address , telephone number information contact person necessary ( eg case miss schedule visit ) . Willing strictly follow study protocol . Legal Responsible research participant ability understand sign free inform consent inform free consent term , accord particularity age group . Understand impossibility participate another clinical trial time participate study . intellectual level legal guardian ( applicable accord age research participant ) filling form registration sign symptoms home . Previous vaccination meningococcus Personal history meningitis kind . Personal history anaphylaxis , asthma , urticaria hypersensitivity reaction previous vaccination allergy hypersensitivity study vaccine component . Use allergy shot antigen within 14 day less prior vaccination . Immunoglobulin Use last 12 month prior vaccination . Use blood product 12 month prior vaccination . Use type vaccine within 30 day study vaccination . The use injectable vaccine least 30 day vaccination study . Chronic use medication , except homeopathic medicine , medication trivial saline nasal use vitamin , birth control . Prior use immunosuppressant cytotoxic medication . individual acceptable make use type medication immunosuppressant dose 6 month nasal steroid allergic rhinitis topical steroid uncomplicated dermatitis . In use systemic treatment high dos steroid ( example , 1 mg / kg / day prednisone least 14 day , equivalent ) history chronic use high power inhale corticosteroid ( e.g. , 800 ug per fluticasone day ) . Use type medication clinical trial period one year prior vaccination . Personal history neurological , cardiovascular , respiratory , hepatic , renal , hematologic , rheumatic autoimmune clinically significant ( disease lead hospitalization prolong treatment ) . Personal history bleed disorder diagnose physician account capillary fragility ( eg . Bruising bleed without justifiable cause ) . Personal history seizure . personal history psychiatric disease hinders adherence protocol , psychosis , obsessivecompulsive neurosis , bipolar disorder treat , diseases require treatment lithium suicidal idea past 5 year prior enrollment . Personal history active malignant disease ( eg type cancer ) treat use study . Personal history sickle cell anemia . Asplenia ( absence spleen removal thereof ) . HIV positive history immunosuppressive disease . Pregnancy breastfeed . Additional criterion female participant childbearing age : negative pregnancy test prior application dos vaccine . The presence disorder , opinion principal investigator , may interfere evaluation study objective . Inability collect blood evaluation prevaccine base ( baseline ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Meningococcal Vaccines</keyword>
	<keyword>Immunogenicity , Reactogenicity Safety Vaccine</keyword>
</DOC>